KaydedilenlerDerginizi ekleyin

Dergiler / Türk Üroloji Dergisi/Turkish Journal of Urology / 2012 / Cilt: 38 - Sayı: 4

Treatment options in benign prostate hyperplasia associated with lower urinary tract symptoms

Benign prostat hiperplazisi ile ilişkili alt üriner sistem semptomlarında tedavi seçenekleri

Ali ATAN
ALTUĞ TUNCEL
Sayfa
228–232
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bu derlemede, benign prostat hiperplazisi ie ilişkili alt üriner sistem semptomlarının tedavi seçenekleri özetlenmiştir.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Benign prostat hiperplazisi, alt üriner sistem semptomlarının en sık nedenidir.
📊
Temel Bulgular & Veri:Benign prostat hipeplazisi’nin tedavisi hayat boyunca akut üriner retansiyonu ve cerrahiye olan gereksinimi azaltmalıdır.
💡
Sonuç & Katkı:Bu derlemede, benign prostat hiperplazisi ie ilişkili alt üriner sistem semptomlarının tedavi seçenekleri özetlenmiştir.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Benign prostat hiperplazisi, alt üriner sistem semptomlarının en sık nedenidir. Benign prostat hipeplazisi’nin tedavisi hayat boyunca akut üriner retansiyonu ve cerrahiye olan gereksinimi azaltmalıdır. Bu derlemede, benign prostat hiperplazisi ie ilişkili alt üriner sistem semptomlarının tedavi seçenekleri özetlenmiştir.

Abstract

Benign prostatic hyperplasia is a common cause of lower urinary tract symptoms. Men who are treated for benign prostatic hyperplasia potentially reduce their lifetime risk of acute urinary retention and the need for benign prostatic hyperplasia-related surgery. In this review, the treatment options of benign prostatic hyperplasia as related to lower urinary tract symptoms are summarized.

🔖

Bu Makaleye Atıf Yap

ATAN, A., TUNCEL, A. (2012). Treatment options in benign prostate hyperplasia associated with lower urinary tract symptoms. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 38 - Sayı: 4, 228–232. https://ajindex.com/articles/328065

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int 2011;107:876-80
  2. Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill B, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics:4-year results from the randomized, double blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int 2011;107:946-54
  3. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006;175:1422-6
  4. Koyanagi T, Artibani W, Correa R, Desgranchamps F, De Reijke TM, Govier F, et al. Initial diagnosis evaluation of men with lower urinary tract symptoms. In: Denis L, Griffiths K, Khoury S, Cocket ATK, McConnel J, Chatelain C, Murphy G, Yoshida O, editors. 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Playmouth: Health Publication;1997. p.179-264
  5. Mc Vary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Management of Benign Prostatic Hyperplasia (BPH) American Urological Association Guideline 2010. http:// www.auanet.org/content/clinical-practice-guidelines/clinicalguidelines. cfm?sub=bph 6. Beckman TJ, Mynderse LA. Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 2005;80:1356-62
  6. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. Guidelines on the management of male lower urinary tract symptoms (LUTS) incl. Benign prostatic obstruction (BPO). EAU Guidelines 2012, European Association of Urology 2012. http://www.uroweb.org/gls/pdf/12_Male_LUTS_LR%20 May%209th%202012.pdf 8. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171:1029-35
  7. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int 2011;107:876-80
  8. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double -blind placebo-controlled studies. Urology 1996;48:406-15
  9. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms sug